Brief: Sensorion Provides Update On SENS-401

Sensorion SA

17/03/2022 06:39

March 17 (Reuters) - Sensorion SA  ALSEN.PA :
    * SENSORION UPDATE ON SENS-401
    * SUPPLEMENTARY ANALYSIS OF THE PHASE 2 AUDIBLE-S STUDY DATA
SHOWS
POSITIVE FINDINGS FOR CERTAIN TRIAL POPULATION SUB-GROUPS WITHIN
SSNHL
    * SENS-401 DEMONSTRATED A STATISTICALLY SIGNIFICANT EFFECT
WITH
THE HIGH DOSE ON PURE TONE AUDIOMETRY (≥ 10 DECIBELS IMPROVEMENT
VERSUS PLACEBO) IN PHASE 2 AUDIBLE-S TRIAL IN SSNHL AT DAY 84 IN
PER PROTOCOL IDIOPATHIC POPULATION (81 PATIENTS) TREATED WITH
CORTICOSTEROIDS – (C. 70% OF STUDY POPULATION)
    * SENSORION WILL CONTINUE ITS JOINT DEVELOPMENT PROGRAM WITH
COCHLEAR LTD FOR HEARING PRESERVATION IN PATIENTS FOLLOWING
COCHLEAR IMPLANTATION
    * SENSORION IS ASSESSING NEXT STEPS FOR SENS-401 IN SSNHL
AND
CISPLATIN-INDUCED OTOTOXICITY (CIO) TO BALANCE CLINICAL
DEVELOPMENT PRIORITIES WITH EFFICIENT CAPITAL ALLOCATION AND
WILL UPDATE THE MARKET IN DUE COURSE

Source text for Eikon:  ID:nBw9ZR8FLa 
Further company coverage:  ALSEN.PA 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))